Literature DB >> 16507188

Efficacy and comparison of 0.5% levobupivacaine with 0.75% ropivacaine for peribulbar anaesthesia in cataract surgery.

A Di Donato1, C Fontana, F Lancia, D Celleno.   

Abstract

BACKGROUND AND
OBJECTIVE: The low cardiovascular and neurological toxicity of levobupivacaine has led to its application as a local anaesthetic in a wide variety of specialist applications including peribulbar block for cataract surgery. The aim of this study was to evaluate the efficacy of levobupivacaine 0.5% and to compare block quality vs. ropivacaine 0.75% in peribulbar anaesthesia.
METHODS: We examined 208 patients subjected to cataract surgery by phacoemulsification who were randomized into two groups according to the anaesthetic used for peribulbar block, namely levobupivacaine 0.5% or ropivacaine 0.75%, both with the addition of hyaluronidase. Nerve block was carried out by injection of 6 mL of the anaesthetic mixture equally distributed between the inferotemporal and superonasal areas. The success of the block was evaluated by determining the time of motor and sensory onset, akinesia score, times of motor and sensory offset and satisfaction of the patient and surgeon after 24 h. Pre-block, post-block and postoperative intraocular pressure as well as the duration of surgical intervention was also determined.
RESULTS: With respect to ropivacaine, levobupivacaine showed a significant reduction (P < 0.001) in the average motor and sensory onset. Both the akinesia score (P < 0.01) and mean motor and sensory offset times were also higher (P < 0.001). Neither the average intervention times nor the satisfaction of the patient/surgeon showed any significant differences between the two groups.
CONCLUSIONS: Levobupivacaine (0.5%) has better anaesthetic properties with respect to 0.75% ropivacaine and is well-suited for peribulbar block in cataract surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507188     DOI: 10.1017/S026502150600041X

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  9 in total

Review 1.  Levobupivacaine: a review of its use in regional anaesthesia and pain management.

Authors:  Mark Sanford; Gillian M Keating
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

2.  Superficial extraconal blockade for vitreoretinal surgery.

Authors:  W Riad; E Abboud; E Al-Harthi; E Kahtani; N Ahmed
Journal:  Saudi J Anaesth       Date:  2010-09

3.  The efficacy of 0.75% levobupivacaine versus 0.75% ropivacaine for peribulbar anesthesia in vitreoretinal surgery.

Authors:  Ashraf M Ghali
Journal:  Saudi J Anaesth       Date:  2012-01

4.  Randomized trial of superficial peribulbar compared with conventional peribulbar anesthesia for cataract extraction.

Authors:  Abdul Kader M Mahfouz; Hassan M Al Katheri
Journal:  Clin Ophthalmol       Date:  2007-03

5.  The quest for effective pain control during suture adjustment after strabismus surgery: a study evaluating supplementation of 2% lidocaine with 0.4% ropivacaine.

Authors:  Howard D Palte; Kara M Cavuoto; Lalitha Sundararaman; Steven Gayer; Joyce Schiffman; Hilda Capo
Journal:  J Pain Res       Date:  2015-01-14       Impact factor: 3.133

6.  Comparison of Olive Tipped and Conventional Steven's Cannula for Sub-Tenon Ophthalmic Anesthesia.

Authors:  Saeed Al-Motowa; Nauman Ahmad; Rajiv Khandekar; Abdul Zahoor
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Oct-Dec

7.  Comparison of levobupivacaine 0.5% or bupivacaine 0.5% both in a mixture with lidocaine 2% for superficial extraconal blockade.

Authors:  Nauman Ahmad; Abdul Zahoor; Abdullah Al Assiri; Sabah Al Jastaneiah; Waleed Riad
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Jul-Sep

8.  Clinical profile of levobupivacaine in regional anesthesia: A systematic review.

Authors:  Sukhminder Jit Singh Bajwa; Jasleen Kaur
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-10

Review 9.  Update on the clinical utility and practical use of ropivacaine in Chinese patients.

Authors:  Man Li; Li Wan; Wei Mei; Yuke Tian
Journal:  Drug Des Devel Ther       Date:  2014-09-09       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.